Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy
The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA
Originally published by CNBC. Summary and curation by DutyStation News.
